Argonaute Autoantibodies as Biomarkers in Autoimmune Neurologic Diseases

Archive ouverte

Do, Le-Duy | Moritz, Christian, P | Muñiz-Castrillo, Sergio | Pinto, Anne-Laurie | Tholance, Yannick | Brugiere, Sabine | Couté, Yohann | Stoevesandt, Oda | Taussig, Michael J. | Rogemond, Véronique | Vogrig, Alberto | Joubert, Bastien | Ferraud, Karine | Camdessanché, Jean-Philippe | Antoine, Jean-Christophe | Honnorat, Jérôme

Edité par CCSD ; American Academy of neurology -

International audience. Objective: To identify and characterize autoantibodies (Abs) as novel biomarkers for an autoimmune context in patients with central and peripheral neurologic diseases.Methods: Two distinct approaches (immunoprecipitation/mass spectrometry\textendash based proteomics and protein microarrays) and patients' sera and CSF were used. The specificity of the identified target was confirmed by cell-based assay (CBA) in 856 control samples.Results: Using the 2 methods as well as sera and CSF of patients with central and peripheral neurologic involvement, we identified Abs against the family of Argonaute proteins (mainly AGO1 and AGO2), which were already reported in systemic autoimmunity. AGO-Abs were mostly of immunoglobulin G 1 subclass and conformation dependent. Using CBA, AGO-Abs were detected in 21 patients with a high suspicion of autoimmune neurologic diseases (71.4% were women; median age 57 years) and only in 4/856 (0.5%) controls analyzed by CBA (1 diagnosed with small-cell lung cancer and the other 3 with Sjögren syndrome). Among the 21 neurologic patients identified, the main clinical presentations were sensory neuronopathy (8/21, 38.1%) and limbic encephalitis (6/21, 28.6%). Fourteen patients (66.7%) had autoimmune comorbidities and/or co-occurring Abs, whereas AGO-Abs were the only autoimmune biomarker for the remaining 7/21 (33.3%). Thirteen (61.9%) patients were treated with immunotherapy; 8/13 (61.5%) improved, and 3/13 (23.1%) remained stable, suggesting an efficacy of these treatments.Conclusions AGO-Abs might be potential biomarkers of autoimmunity in patients with central and peripheral nonparaneoplastic neurologic diseases. In 7 patients, AGO-Abs were the only biomarkers; thus, their identification may be useful to suspect the autoimmune character of the neurologic disorder. Classification of Evidence This study provides Class III evidence that AGO-Abs are more frequent in patients with autoimmune neurologic diseases than controls.

Suggestions

Du même auteur

Anti-AGO1 Antibodies Identify a Subset of Autoimmune Sensory Neuronopathy

Archive ouverte | Moritz, Christian, P | CCSD

International audience. Background and ObjectivesAutoantibodies (Abs) improve diagnosis and treatment decisions of idiopathic neurologic disorders. Recently, we identified Abs against Argonaute (AGO) proteins as pot...

Immune Checkpoint Inhibitor-Related Cerebellar Toxicity: Clinical Features and Comparison with Paraneoplastic Cerebellar Ataxia

Archive ouverte | Dentoni, Marta | CCSD

International audience. Abstract Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, and the association with immune-related adverse events (irAEs) is well-established. However, cerebellar irAEs...

TRIM9 and TRIM67 Are New Targets in Paraneoplastic Cerebellar Degeneration

Archive ouverte | Do, Le Duy | CCSD

International audience. To describe autoantibodies (Abs) against tripartite motif-containing (TRIM) protein 9 and 67 in two patients with paraneoplastic cerebellar degeneration (PCD) associated with lung adenocarcin...

Chargement des enrichissements...